US 6,982,256 B2
Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
Christine Votteler, Maselheim-Sulmingen (Germany); and Bernd Kruss, Hochdorf (Germany)
Assigned to Boehringer Ingelheim Pharma KG, Ingelheim (Germany)
Filed on Sep. 09, 2002, as Appl. No. 10/237,918.
Claims priority of provisional application 60/323477, filed on Sep. 19, 2001.
Claims priority of application No. 101 44 030 (DE), filed on Sep. 07, 2001.
Prior Publication US 2003/0069207 A1, Apr. 10, 2003
Int. Cl. A61K 31/724 (2006.01)
U.S. Cl. 514—58 16 Claims
 
1. A pharmaceutical composition comprising a mixture or a complex, or both, of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-beazoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, and a pharmacologically acceptable cyclodextrin.